Anzeige
Mehr »
Freitag, 12.12.2025 - Börsentäglich über 12.000 News
Schock aus China - Lithium zieht an, Antimon wird politisch: Diese Aktie könnte 2026 durchstarten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PV71 | ISIN: CNE100003PJ8 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
VENUS MEDTECH HANGZHOU INC Chart 1 Jahr
5-Tage-Chart
VENUS MEDTECH HANGZHOU INC 5-Tage-Chart

Aktuelle News zur VENUS MEDTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.11.VENUS MEDTECH-B (02500): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING1
19.11.VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE1
VENUS MEDTECH Aktie jetzt für 0€ handeln
17.11.Venus Medtech (Hangzhou) Inc.: Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion228Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting. LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech...
► Artikel lesen
14.11.VENUS MEDTECH-B (02500): SUPPLEMENTAL ANNOUNCEMENT PROPOSED ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND ENTRY INTO THE SUPPLEMENTAL AGREEMENTS-
12.11.VENUS MEDTECH-B (02500): PROXY FORM FOR USE AT THE EGM-
12.11.VENUS MEDTECH-B (02500): NOTICE OF EXTRAORDINARY GENERAL MEETING3
12.11.VENUS MEDTECH-B (02500): (1) MAJOR TRANSACTION IN RELATION TO DISPOSAL OF PROPERTY AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING3
12.11.BRIEF: Venus Medtech sells Hangzhou project for 375 million yuan2
11.11.VENUS MEDTECH-B (02500): MAJOR TRANSACTION IN RELATION TO DISPOSAL OF PROPERTY CLOSURE OF REGISTER OF MEMBERS AND CHANGE IN USE OF PROCEEDS FROM THE INITIAL ...1
27.10.Venus Medtech's Cardiovalve completes enrollment in tricuspid valve replacement trial1
25.10.Venus Medtech (Hangzhou) Inc.: Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement630The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/...
► Artikel lesen
24.10.VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT COMPLETION OF FULL PATIENT ENROLLMENT FOR CONFIRMATORY CLINICAL STUDY OF CARDIOVALVE TTVR-
29.09.VENUS MEDTECH-B (02500): 2025 INTERIM REPORT1
28.08.VENUS MEDTECH-B (02500): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025-
18.08.VENUS MEDTECH-B (02500): DATE OF BOARD MEETING1
05.08.Venus Medtech (Hangzhou) Inc.: Court Sides with Cardiovalve in Edwards patent spat230HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary...
► Artikel lesen
27.06.VENUS MEDTECH-B (02500): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS1
27.06.VENUS MEDTECH-B (02500): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
27.06.VENUS MEDTECH-B (02500): (1) POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING; AND (2) ELECTION OF CHAIRMAN OF THE BOARD AND MEMBERS OF COMMITTEES OF THE ...1
22.04.Venus Medtech (Hangzhou) Inc.: Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations504HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1